TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
1. TGTX starts Phase 3 trial for subcutaneous BRIUMVI in RMS. 2. BRIUMVI is approved for IV use; subcutaneous version may broaden market. 3. Trial aims for non-inferior exposure to IV BRIUMVI by week 24. 4. Success could mean FDA approval by 2028. 5. CEO emphasizes flexibility and patient choice in treatment options.